Her-2/neu Overexpression Due to Polysomy 17 in Breast Cancer: Molecular Testing to Guide Therapeutic Options

Publisher： Karger

E-ISSN： 2296-5262|34|7|356-360

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.34, Iss.7, 2011-06, pp. : 356-360

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HER2: The Neu Prognostic Marker for Breast Cancer

By Tsongalis Gregory J.   Ricci Jr. Andrew  

Critical Reviews in Clinical Laboratory Sciences, Vol. 38, Iss. 2, 1998-03 ,pp. : 167-182

Informa Healthcare

Access to resources Recommend Favorite

HER2/neu vaccines in breast cancer

By Khoo Steven   Ponniah Sathibalan   Peoples George E  

Women's Health, Vol. 2, Iss. 2, 2006-03 ,pp. : 217-223

Future Medicine

Access to resources Recommend Favorite

Targeting Her-2/neu in Breast Cancer: As Easy as This!

By  

Oncology, Vol. 74, Iss. 3-4, 2008-08 ,pp. : 150-157

Karger

Access to resources Recommend Favorite

HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic Significance

By  

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 154-161

Karger

Access to resources Recommend Favorite

What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer

By Trosman Julia R   Weldon Christine B   Schink Julian C   Gradishar William J   Benson Al B  

Journal of Comparative Effectiveness Research, Vol. 2, Iss. 4, 2013-07 ,pp. : 461-477

Future Medicine

Access to resources Recommend Favorite